Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. März 2020 12:07 ET | Quelle: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Presents Health State Utility Index Data on Severity of Fragile X Syndrome (FXS) and Diagnostic Challenges Faced by Caregivers

- Data Presented at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Meeting - - Health State Utility Index Data Estimate the Significant Health Burden of FXS, and Suggest the...
26. Februar 2020 06:50 ET | Quelle: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Announces the Completion of Enrollment in the Pivotal CONNECT-FX Trial of Zygel™ in Fragile X Syndrome

DEVON, Pa., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
22. Oktober 2019 12:09 ET | Quelle: GL Communications Inc.

Analog Legacy Protocol Enhancements

GAITHERSBURG, Md., Oct. 22, 2019 (GLOBE NEWSWIRE) -- GL Communications Inc., a global leader in telecom test and measurement solutions, addressed the press regarding the T1 E1 Protocol Analyzer...
12. Dezember 2018 17:30 ET | Quelle: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment with ZYN002

- Patients Experienced a 77% Improvement in Aberrant Behaviors Associated with Social Avoidance Compared to Baseline after One Year of ZYN002 Treatment - - Presentation Today at the 57th Annual...